Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Opinion
Video

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Related Videos
Sumanta Kumar Pal, MD, FASCO,
Video 2 - "Navigating Glioblastoma Imaging: The Patient Journey from Diagnosis to Treatment "
Video 1 - "Neuroimaging of Glioblastoma"
Kohei Shitara, MD
Video 11 - "Pioneering Breakthroughs in HCC Treatment"
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Kian-Huat Lim, MD, PhD
Benjamin Garmezy, MD
Video 10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Related Content
Renal Cell Carcinoma - stock.adobe.com

Retrospective Data Shed Light on Prognostic Value of PD-L1 Expression in Metastatic Papillary RCC

May 27th 2024
Article
Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024
Podcast
Eliezer Van Allen, MD, chief, Division of Population Sciences, physician, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School

Addressing Research Into the Association Between Tumor Mutations and Responses in RCC

May 21st 2024
Article
Jack Khouri, MD

Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis

November 9th 2023
Podcast
FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 21st 2024
Article
FDA

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024
Article